Clinical trials: Prostatic Adenocarcinoma
Prostate Adenocarcinoma
ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma
This study will determine the delayed neurotoxicity (12 months) of a hypofractionated high dose irradiation (3 Gy x 9) associated with zoledronic acid.
- Trial name
- GEMO (NCT01219790)
- Testing
- external radiotherapy, Acide zoledronic
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- Institut Cancerologie de l'Ouest
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer
Phase II trial to study the effectiveness of combining zoledronate with BMS-275291 in treating patients who have prostate cancer that has not responded to previous hormone therapy.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00039104
- Testing
- rebimastat, zoledronic acid, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Breast Cancer
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
This clinical trial studies the effect of four different intervention components "tools" on body weight, nutrition, and physical activity in cancer survivors.
- Conditions
- Bladder Cancer, Breast Cancer, Colon Cancer, Endometrial Cancer
- Trial name
- TTBF (NCT05056077)
- Testing
- Counseling, Educational Intervention, Health Education
- Where
- United States
- Volunteers
- 353 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Pomegranate Extract in Treating Patients With Rising Prostate-Specific Antigen Levels After Surgery or Radiation Therapy for Localized Prostate Cancer
RATIONALE: Pomegranate extract may keep prostate cancer from growing in patients with rising prostate-specific antigen (PSA) levels after surgery or radiation therapy for localized prostate cancer.
- Trial name
- NCT00336934
- Testing
- pomegranate juice
- Volunteers
- 183 people
- Sponsor
- Roll International Corporation
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
This randomized phase II trial is studying bicalutamide, goserelin, or leuprolide acetate to see how well they work when given with or without cixutumumab in treating patients with newly diagnosed metastatic prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT01120236
- Testing
- Bicalutamide, Cixutumumab, Goserelin Acetate
- Where
- 170 sites in United States, Canada
- Volunteers
- 211 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation Therapy
RATIONALE: Implant radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. PURPOSE: This phase II trial is studying the side effects and how well ultrasound-guided implant radiation…
- Trial name
- NCT00450411
- Testing
- 125-Iodine, 103-palladium
- Where
- 17 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00016913
- Testing
- carboplatin, estramustine, paclitaxel
- Where
- 23 sites in United States
- Volunteers
- 34 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer, Prostate Adenocarcinoma
MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca
Phase II non-inferiority randomized trial of annual systematic biopsies versus mpMRI and targeted biopsies for men with low risk prostate cancer on active surveillance with any volume Gleason's Score 6, but no prior MRI imaging…
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Multiparametric MRI, Gleason's Score 6
- Trial name
- NCT02564549
- Testing
- TRUS-guided biopsy, mpMRI with targeted biopsy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Virginia Commonwealth University
Prostate Cancer
Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known which radiation therapy regimen is more effective in treating patients with relapsed prostate cancer.
- Trial name
- NCT01272050
- Testing
- radiation therapy
- Where
- 28 sites in Belgium, Germany and 1 more
- Volunteers
- 350 people
- Sponsor
- Swiss Cancer Institute
Prostate Adenocarcinoma
ERG Protein Expression in Prostatic Adenocarcinoma and Its Clinicopathological Features
Evaluation the ERG expression in prostatic acinar adenocarcinoma and its association with clinicopathological features.
- Trial name
- NCT04825691
- Testing
- Immunohistochemistry of prostate biopsy
- Volunteers
- 50 people
- Sponsor
- Assiut University
Prostate Cancer
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Estramustine may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00052845
- Testing
- docetaxel, estramustine phosphate sodium, exisulind
- Where
- 80 sites in United States, Canada and 1 more
- Volunteers
- 80 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Ixabepilone in Treating Patients With Metastatic Prostate Cancer
Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00087139
- Testing
- ixabepilone
- Where
- 162 sites in United States
- Volunteers
- 124 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether radiation therapy to the prostate and pelvis is more effective than radiation therapy to the prostate alone in treating…
- Trial name
- NCT00003607
- Testing
- radiation therapy
- Where
- 23 sites in France
- Volunteers
- 450 people
- Sponsor
- UNICANCER
Prostatic Neoplasms
Efficacy and Safety Study of Xyotax to Treat Prostate Cancer
The purpose of this study is to determine whether Xyotax, a conjugate of the taxane drug paclitaxel, is effective in the treatment of prostate cancer that is no longer responsive to hormone therapy.
- Trial name
- NCT00446836
- Testing
- Paclitaxel polyglumex (Xyotax)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- The Methodist Hospital Research Institute
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Background: Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands. Prostate cancer is the most common cancer in men in the United States.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma
- Trial name
- NCT07667400
- Testing
- SX-682, DTX
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer
RATIONALE: Quality of life assessment in patients undergoing prostate cancer treatment may help determine the intermediate-term and long-term effects of surgery and brachytherapy.
- Trial name
- NCT00052481
- Testing
- quality-of-life assessment
- Where
- 13 sites in United States
- Volunteers
- 500 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer, Solid Tumor
Safety Study of CALAA-01 to Treat Solid Tumor Cancers
Rationale: CALAA-01 is a targeted therapeutic designed to inhibit tumor growth and/or reduce tumor size. The active ingredient in CALAA-01 is a small interfering RNA (siRNA).
- Trial name
- NCT00689065
- Testing
- CALAA-01
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Calando Pharmaceuticals
Prostate Cancer
A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1
This study investigates the use of the patients own immune cells to treat prostate cancer. Cells are taken from the patient and grown in the laboratory to become specialized immune cells called dendritic cells.
- Trial name
- MUC1 (NCT00852007)
- Testing
- DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Hamilton Health Sciences Corporation
Prostate Cancer
Docetaxel Compared With Observation in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00376792
- Testing
- docetaxel, active surveillance, adjuvant therapy
- Where
- 8 sites in Denmark, Finland and 3 more
- Volunteers
- 396 people
- Sponsor
- Scandinavian Prostate Cancer Group
Advanced Cancer
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families.
- Trial name
- NCT02219711
- Testing
- MGCD516
- Where
- 43 sites in United States, South Korea
- Volunteers
- 193 people
- Sponsor
- Mirati Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.